What Will Icahn Do With Amylin?

It's fun to peruse the Form 13-Fs of the most successful investors. Not only can you get investment ideas, but if you’re an activist investor, you can get a sneak peek at the next company your favorite investors are planning on flexing their muscles against.

Carl Icahn recently took an initial position now worth around $200 million in Amylin Pharmaceuticals (Nasdaq: AMLN  ) , and stockholders must be wondering about his motivation for the purchase. Will he advocate for the company's sale, like he did with Biogen Idec (Nasdaq: BIIB  ) and MedImmune, which actually did get purchased by AstraZeneca (NYSE: AZN  ) ? Or will he take a more mundane (for him) role and just advocate for management changes, like he did with ImClone Systems (Nasdaq: IMCL  ) ?

I'm guessing Icahn will choose the latter, since selling the company seems like a difficult proposition. Amylin's present and its near-term future are both tied to its diabetes drug Byetta and a follow-on once-weekly version, both of which are partnered with Eli Lilly (NYSE: LLY  ) . Any large pharma that’s interested in boosting its diabetes offerings might not be interested in working hand-in-hand with Eli Lilly. That leaves Amylin's partner as the only likely candidate for a purchase, and it's hard to get a bidding war going with just one player.

It's easy to predict what Icahn's beef with management will be. Sales of Byetta have begun to stagnate, and competition from Novo Nordisk (NYSE: NVO  ) is right on its heels. He'll likely also complain about Amylin's development of its once-weekly version of Byetta. The drug should increase sales substantially, since it’s much more patient-friendly, but it likely won't be available until 2010, although the pivotal clinical trial is already complete. Still, unless he's planning on grabbing a hammer to help build the new plant, I'm not sure how Icahn is going to help management get the drug to market more quickly.

Until the Investor of the Year nominee comes out and tells us his thinking -- after he finishes dealing with Yahoo! (Nasdaq: YHOO  ) ? -- we'll all be in the dark. But since he's generally had more successes than failures, I don't think Amylin's investors should be upset about Icahn joining their ranks.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Eli Lilly is a Motley Fool Income Investor pick. Biogen is a Motley Fool Stock Advisor recommendation. The Fool's disclosure policy advocates for you.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 647963, ~/Articles/ArticleHandler.aspx, 10/25/2014 5:06:26 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement